| Trial ID: | L2448 |
| Source ID: | NCT02536248
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin Therapy and Kinetics of Inflammatory Markers
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02536248/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period, 6 weeks | Secondary: Measurement of Serum Amyloid A Production Rate With Stable Isotope During Postprandial Period, 6 weeks|Measurement of L-selectin Production Rate With Stable Isotope During Postprandial Period, 6 weeks|Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period, 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: Laval University | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-08-01
|
| Completion Date: |
2017-10-31
|
| Results First Posted: |
2020-05-13
|
| Last Update Posted: |
2020-05-13
|
| Locations: |
Laval University, Quebec City, Quebec, G1V 0A6, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02536248
|
